[RNA as pharmaceuticals].
Takano-Ohmuro
Hiromi
H
h_ohmuro@musashino-u.ac.jp
D000818:Animals; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D052157:Aptamers, Nucleotide; D002986:Clinical Trials as Topic; D015195:Drug Design; D064420:Drug-Related Side Effects and Adverse Reactions; D018390:Gene Targeting; D006801:Humans; D004364:Pharmaceutical Preparations; D011786:Quality Control; D012313:RNA / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use; D000069579:Ranibizumab
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D052157:Aptamers, Nucleotide; D004364:Pharmaceutical Preparations; C495058:pegaptanib; D012313:RNA; D000069579:Ranibizumab